Researchers say the gut microbiome may be a viable targetable biomarker to improve immunotherapy responses in those with glioblastoma and a range of other cancers.
Researchers found a positive correlation between glioblastoma cell proliferation and lactate metabolic indicators. Based on this observation, the researchers developed a biomimetic formulation using targeted delivery agents for lactate metabolism-based synergistic therapy against glioblastoma brain cancer.
A new implantable pump system safely and effectively bypasses the blood-brain barrier to deliver chemotherapy drugs to those with glioblastoma brain cancer.
Results of a phase three clinical trial of a novel brain cancer vaccine, DCVax-L, that uses a patient's stem cells to target cancer cells extend survival by many months to years for glioblastoma patients.
Combining machine learning technology with neuroimaging data, clinicians will be better able to fully analyze a patient's glioblastoma brain tumor and predict cancer progression.
In glioblastoma brain cancer, EGFR (HER1) genetic mutations lead to a movement of a large part of the extracellular region of the protein. This activates the intracellular area in a particular way that drives glioblastoma tumor development.